PER® Miami Breast Cancer Conference | Conference

Applying RxPONDER to Clinical Practice

March 30th 2021

Faculty from the Miami Breast Cancer Conference® discuss how to apply the RxPONDER data to clinical practice.

Intravenous Cetirizine Prevents Infusion Reactions From Paclitaxel in Breast Cancer, Other Tumors

March 22nd 2021

Intravenous cetirizine showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions in patients with cancer who are undergoing treatment with an anti-CD20 antibody or paclitaxel.

Are New Ways to Reduce Positive Margins in Breast Cancer Hope or Hype?

March 10th 2021

There are a number of strategies to reduce margin positivity, particularly after partial mastectomy, but the relative effectiveness of each varies, as do the data that support their use.

PARP Inhibitors Remain Key Players in Metastatic Breast Cancer

March 8th 2021

Olaparib and talazoparib failed to demonstrate statistically significant improvements in overall survival compared with chemotherapy in pretreated patients with BRCA1/2-mutant metastatic HER2-negative breast cancer. However, the results are unlikely to affect the drugs’ utility in practice, given that both agents continue to show favorable tolerability and disease control

An Autopsy of Breast Cancer Management Amidst the COVID-19 Pandemic

March 7th 2021

One year into the COVID-19 pandemic has allowed for some reflection on the different evolutions that the oncology community went through in response to the many challenges posed by the virus.

Biomarkers Help Predict the Role of Chemotherapy in Biologic Aging

March 7th 2021

Stimuli for biologic aging include ionizing radiation, ultraviolet light, diet, exercise, oxidative stresses, and perhaps, worst of all, smoking. All of these can trigger intracellular processes, including DNA methylation, or epigenetic change, telomere shortening and damage, DNA damage, and mitochondrial dysfunction.

Genomics, AI, and Demography Will Remake Cancer Care by 2030

March 7th 2021

A wave of approvals and a rapidly evolving treatment landscape could make the next decade a watershed period in breast cancer care.

Addressing Treatment Disparities Among Younger Women with Breast Cancer

March 6th 2021

Even in 2021, disparities in outcomes of younger women with breast cancer vs their older counterparts remain; addressing behavioral issues and psychological concerns in this population could vastly improve their quality of life, treatment adherence, and ultimately, survival.

The Marshall Family Faces Off Against TNBC

March 6th 2021

Off Our Chests: A Candid Tour Through the World of Cancer is a memoir that dives into Liza Marshall’s breast cancer journey.

Neoadjuvant Checkpoint Inhibition Shows Promise in TNBC, But Is Not Ready for Clinical Use

March 6th 2021

Although phase 3 data suggest that the addition of checkpoint inhibitors to neoadjuvant chemotherapy could improve pathologic complete response rates for patients with early-stage triple-negative breast cancer, immature data and the risk of long-term toxicity indicate that the therapy is not ready for primetime

Dr. Kalinsky on the Potential of ADCs Across Breast Cancer Subtypes

March 6th 2021

Kevin Kalinsky, MD, MS, discusses the potential of antibody-drug conjugates across breast cancer subtypes.

Dr. Rugo on the Benefit of Margetuximab Plus Chemotherapy in HER2+ Metastatic Breast Cancer

March 6th 2021

Hope S. Rugo, MD, discusses the benefit of margetuximab-cmkb in patients with HER2-positive breast cancer who have received prior HER2-targeted therapies.

New HER2-Targeting Therapies Jostle for a Place in the Treatment Lineup

March 6th 2021

The introduction of new therapies for patients with recurrent HER2-positive metastatic breast cancer has resulted in a crowded landscape for third-line treatments and beyond, raising questions about how best to sequence a wealth of options.

Research Moves Full Steam Ahead With Brain Metastases, Leptomeningeal Disease in Breast Cancer

March 6th 2021

Targeted agents and chemotherapy regimens are at the crux of systemic research efforts focused on improving outcomes for patients with breast cancer who have brain metastases and/or leptomeningeal disease.

Personalizing HER2-Targeted Treatment Strategies in Early-Stage and Advanced Breast Cancer

March 5th 2021

Debu Tripathy, MD, discusses some of the unanswered clinical questions that remain for patients with HER2-positive disease and some strategies for personalizing treatment in the neoadjuvant and adjuvant settings.

Dr. Tripathy on Efforts to Minimize Risk of Recurrence in Early-Stage HER2+ Breast Cancer

March 5th 2021

Debu Tripathy, MD, discusses efforts being made to minimize the risk of disease recurrence in patients with early-stage HER2-positive breast cancer.

Dr. Olopade on Racial Disparities in Breast Cancer Outcomes

March 5th 2021

Olufunmilayo Falusi Olopade, MD, FACP, discusses racial disparities in breast cancer outcomes.

Targeted Therapies Continue to Shape Future Breast Cancer Paradigm

March 5th 2021

With the identification of numerous molecular abnormalities that can affect treatment and the course of disease in patients with breast cancer, it’s become understood that genetic profiling can define clinical trial eligibility, the presence or absence of aberrations help to drive treatment decisions, and variants can be predictive for response or resistance.

Local Management in Stage IV Breast Cancer Requires More Refinement

March 5th 2021

Although there is evidence to suggest that surgery with or without radiation therapy can be utilized in some patients with stage IV breast cancer who have experienced locoregional progression or symptoms to some success with regard to locoregional disease control, most patients will not achieve a survival benefit.

Adjuvant CDK4/6 Inhibition Shows Potential in Early HR+/HER2- Breast Cancer, But More Data Are Needed

March 5th 2021

CDK4/6 inhibitors plus aromatase inhibitors have shown benefit as frontline treatment for patients with hormone receptor–positive, HER2-negative advanced breast cancer, but more data are needed to determine their role as adjuvant therapy before they are adopted into standard practice for patients with early-stage disease.